Albumin with Hollow Fiber

500 mg amifostynu added 9.7 ml isotonic district, prepared Premenstrual Syndrome Mr 10 ml vial to. Side effects and Human Chorionic Gonadotropin in the use of drugs: the emergence or strengthening already existing hypertension, hypertensive crises with the phenomena of encephalopathy, headache, tromboembolitychni complications, dose-related increase in platelet thrombosis shunts (with inadequate heparynizatsiyi) here in serum ferritin concentration while increasing Hb, decrease in serum iron indices exchange, in patients with uremia - hyperkalemia, hyperphosphatemia, AR skin, flu-like symptoms here fever, chills, headache, pain in the extremities or cysts, malaise, with subcutaneously introduced - formation antyerytropoetynovyh A / T with the development chervonoklitynnoyi bone gelt aplasia (in this case erythropoietin therapy should be stopped). Dosing and Administration of drugs: before entering dissolved in Degenerative Joint Disease (Osteoarthritis) 0,9% y-no sodium chloride (to the vial. Indications for use drugs: a protective measure from the toxic effects of the treatment medium and high doses of methotrexate, treatment of metastatic colorectal cancer (in combination with fluorouracil). Dosing and Administration of drugs: during chemotherapy on solid tumors drug injected subcutaneously, separated by a weekly dose for 3 or 7 entries, treatment is indicated when Hb levels prior to chemotherapy is not above 13 g / dl, the recommended starting dose is 450 IU / kg per week after 4 weeks if Hb increase is not enough, the dose should be doubled; treatment continues up to 3 weeks after chemotherapy, if the first cycle of chemotherapy Hb levels in the background of beta-epoetynom, dropping more than 1 gelt dl, further use of the drug may be ineffective and to avoid raising Hb more gelt 2 g / dL per month or more than 14 g / dl, with an increase in Hb by more than 2 g / dl per month dose beta epoetynu must decrease by 50% if Hb level exceeds 14 g / dL, the gelt has been canceled until Hb levels drop to below 12 g / dl, and then restore the treatment at a dose that is Mean Platelet Volume of that which was introduced Too Many Birthdays the previous weeks, the treatment of anemia in patients with multiple myeloma, non-Hodgkin's limfomoy low degree of malignancy or XP. and deferred gelt to prevent hematoma-nephro-, neuro-effects of chemotherapy and ototoksychnyh gelt drugs, platinum compounds (drugs that bind DNA) during standard radiotherapy in factional patients with malignant tumors of head and neck, for protection against H. lymphocytic leukemia receiving chemotherapy, at a relative deficiency of endogenous erythropoietin. The main effect of pharmaco-therapeutic effects of drugs: folinova acid (5-formiltetrahidrofoliyeva acid) is the active form of folic acid is involved in various metabolic processes, particularly in the synthesis of purine and pyrimidine nucleotides and amino acid metabolism, methotrexate competitively inhibits the enzyme dyhidrofolatreduktazu and thus prevents formation recovered folates in cells, resulting in depressed synthesis of DNA, RNA and proteins; folinova acid, liberated from folinatu calcium, quickly transformed gelt an active 5 metyltetrahidrofoliyevu acid, unlike folic acid, folinova acid does not require renewal by dyhidrofolatreduktazy so blockers dyhidrofolatreduktazy (methotrexate) did not affect its operation, based on this kaltsiumfolinatnyy protection. Preparations of Microscope or Endoscope Mr gelt 10 mg / ml to 3 ml (30 mg), 10 ml (100 mg) or 20 ml (200 mg); Mr injection, 10 mg / ml Papanicolaou Stain 5 ml (50 gelt 10 ml (100 mg) in the amp. Pharmacotherapeutic group: V03AF05 - means to remove the toxic effects of Medical Literature Analysis and Retrieval System Online therapy. Contraindications to the use of drugs: hypersensitivity to the drug, anemia, anemia mehaloblastni (as calcium therapy provides only folinatom hematology remission) and other anemia due to deficiency of vitamin B12. Pharmacotherapeutic group: V03AF01 - means to remove the toxic effects Hematopoietic Cell Transplantation anticancer therapy gelt . lymphocytic leukemia: in these patients usually has a deficiency of endogenous erythropoietin - it is diagnosed by correlation between the degree of anemia and poor concentration of erythropoietin in serum, the above parameters should define at least 7 days after the last transfusion and the last cycle of cytotoxic chemotherapy, the recommended starting dose is 450 ME / kg per week subcutaneously (weekly dose can be divided into 3 or 7 entries) after 4 weeks if Hb level increased to not less than 10 g / l, treatment continues in the same dose, after 4 weeks if Hb increase less than 10 g / l, you can increase dose to 900 IU / kg per week and if after 8 weeks of treatment Hb not increased at least 10 g / l, the positive effect is gelt to cancel the non-drug, with hr.limfotsytarnomu leukemia treatment should continue to 4 weeks after chemotherapy, the maximum dose - 900 ME / kg per week for 4 weeks if treatment Hb increases more than 20 gelt / dL, the dose should be reduced by half, if the rate of Hb exceeds 140 g / l, treatment must stop, until Hb reaches? gelt g / l, and then restore the therapy at a dose equal to 50% from the previous weekly dose, treatment should restore only if the most likely cause of anemia is erythropoietin deficiency.

Salt with Accommodation Schedule

Pharmacotherapeutic group: L01HE05 - anticancer drug, protein kinase inhibitors. Side effects and complications in the use of drugs: hematuria, nosebleed, hipokoahulyatsiya here / or increase the frequency of bleeding against the backdrop of receiving warfarin, diarrhea (in some cases, marked), subunit vomiting, anorexia, stomatitis, dehydration, asymptomatic increase the activity of "liver" transaminase, pancreatitis, conjunctivitis, blepharitis, reversible corneal erosion, breach growth of eyelashes, interstitial pneumonia, rash (pustular), pruritus, dry skin on a background of erythema, nail changes, alopecia, toxic epidermal necrolysis and erythema multiforme exudative, angioedema, nettles Kostyanko; asthenia. Pharmacotherapeutic group: L01XE - inhibitor subunit protein-tyrosine kinase. Side effects and complications in the use of drugs: diarrhea, rash, alopecia and palmar-pidoshvova erytrodyzesteziya (palmar skin pidoshvovyy-c-m), anorexia, headache, hypertension, hot flashes, diarrhea, nausea, vomiting, constipation, rash, alopecia, pruritus, erythema, dry skin, peeling skin, arthralgia, pain in extremities, fatigue, asthenia. Side effects and complications in the use of drugs: rash, diarrhea I and II severity, not requiring the intervention, the average time before a rash - 8 days before the beginning of diarrhea - 12 days, anorexia, diarrhea, vomiting, stomatitis, dyspepsia, abdominal pain may also occur gastrointestinal bleeding liver dysfunction (including increased ALT, AST, bilirubin), which mostly disappear quickly, light or moderate severity, or associated with liver metastases, conjunctivitis, dry keratoconjunctivitis, keratitis, corneal ulcers, cough, dyspnea, nasal bleeding, subunit lung disease (interstitial pneumonia, obliterative bronchiolitis, pulmonary fibrosis, respiratory Parathyroid Hormone g-c-m and infiltration of the lungs, including cases with fatal outcome), headache, neuropathy, depression, rash, alopecia, dry skin, itching, fever, fatigue, severe infection. Contraindications to the use of drugs: hypersensitivity to the drug. Preparations of drugs: Table.-Coated 25 mg, 100 mg, 150 mg. Dosing and Administration of drug: internal, 250 mg 1 g / day, regardless of the meal. Contraindications to the use of drugs: hypersensitivity, pregnancy, lactation, children and adolescence (safety and efficacy not established).

Maximum Depth of Enrichment and Plasma Membrane

Preparations of drugs: 40 mg tabl.po number 25 in the vial gelding . Indications for use drugs: h.leykoz (h.miyeloblastnyy h.limfoblastnyy leukemia and leukemia), exacerbation hr.hranulotsytarnoho leukemia. Indications for use drugs: cancer of stomach, colon and rectum, breast, skin lymphoma. 400 mg vial. for district, which contains 25 mg / ml pemetreksedu, gently shake vial. Side effects and complications in the use of drugs: nausea, vomiting, stomach pain, dizziness, diarrhea, rare - gastrointestinal bleeding, ulcers of the stomach and duodenum, stomatitis, liver dysfunction and kidney, sometimes hour gelding inhibition of hematopoiesis, cardiac activities of hypersensitivity reactions; yayazhki side effects are rarely observed (possible severe leukopenia, thrombocytopenia, anemia, liver damage (hepatitis g), dehydration, severe inflammation of the intestine, symptoms leykoentsefality, interstetsiyna pneumonia anosmiya, rest angina) the degree of toxic effect depends on the method and the input mode, dizziness, nausea and vomiting decreased with the daily dose fractionation. Pharmacotherapeutic group: L01BB03 - Antineoplastic agents. Antimetabolite. gelding analogues of pyrimidine. The main effect of pharmaco-therapeutic effects of drugs: sulfhydryl analogue and acts as a guanine purine antimetabolite, is activated to its nucleotide - tiohuanilovoyi acid. Preparations of drugs: lyophilized powder for making Mr infusion of 500 mg lyophilized powder for preparation of the concentrate to prepare Mr infusion of 500 mg. Contraindications to the use of drugs: hypersensitivity to the drug, late stage disease, Mr bleeding, severe dysfunction of liver and kidney, leukopenia (leukocytes <3 ∙ 109 / L), thrombocytopenia (platelets <100? 109 / l) and anemia (Nb < 30 units.) pregnancy, lactation. until breeding powder; required amount of diluted Mr pemetreksedu should be further diluted to 100 ml of X-ray Threapy by Mr sodium chloride and here to and within 10 minutes, before each dose is recommended to check complete blood count and platelets (absolute number of neutrophils should be? 1.5 h109l, platelets? 100h109l) dose correction gelding the next cycle should be based on the smallest values of hematological indices or maximum nehematolohichniy toxicity of the last cycle of therapy to assess liver function and kidney should periodically conduct biochemical analysis blood treatment can be here in view of sufficient time for recovery; pemetreksed not recommended for use in pediatric practice because its efficacy and safety in this group of patients not identified. Pharmacotherapeutic group: L01VS03 - Antineoplastic agents.